| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/26/2004 | EP1421084A1 Polycyclic guanine phosphodiesterase v inhibitors |
| 05/26/2004 | EP1421083A1 Novel imidazopyridine compounds with therapeutic effect |
| 05/26/2004 | EP1421082A1 New piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity |
| 05/26/2004 | EP1421079A1 Novel compounds |
| 05/26/2004 | EP1421078A1 Beta-3 adrenergic agonists |
| 05/26/2004 | EP1421077A2 Novel pyrazole analogs acting on cannabinoid receptors |
| 05/26/2004 | EP1421075A1 Piperidine derivatives useful as ccr5 antagonists |
| 05/26/2004 | EP1421074A1 Novel compounds |
| 05/26/2004 | EP1421071A2 Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators |
| 05/26/2004 | EP1421070A1 New piperidinyl derivates as modulators of chemokine receptor activity |
| 05/26/2004 | EP1421069A1 Process for the preparation of cyclopenta[g]quinazoline derivatives |
| 05/26/2004 | EP1421067A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 05/26/2004 | EP1421065A1 Hydrazinopeptoids and their uses for treating cancers |
| 05/26/2004 | EP1421062A1 Novel cyclohexyl sulphones |
| 05/26/2004 | EP1421061A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| 05/26/2004 | EP1421060A1 Antiviral protease inhibitors |
| 05/26/2004 | EP1421058A2 Processes for the production of alpha-difluoromethyl ornithine (dfmo) |
| 05/26/2004 | EP1421057A1 Chemotherapeutic agents |
| 05/26/2004 | EP1420880A2 Stabilization and terminal sterilization of phospholipid formulations |
| 05/26/2004 | EP1420851A1 Use of a blood-flow decrease preventing agent in conjunction with insufflating gas |
| 05/26/2004 | EP1420834A1 Hormone-coated stent for preventing stenosis or atherosclerosis |
| 05/26/2004 | EP1420829A2 Immunomodulatory compositions, formulations, and methods for use thereof |
| 05/26/2004 | EP1420828A2 Lipophilic drug compositions |
| 05/26/2004 | EP1420827A1 5-cnac as oral delivery agent for parathyroid hormone fragments |
| 05/26/2004 | EP1420826A2 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof |
| 05/26/2004 | EP1420824A2 Compound |
| 05/26/2004 | EP1420821A2 Immunologically significant herpes simplex virus antigens and methods for using same |
| 05/26/2004 | EP1420809A1 Use of cyclopenta[g]quinazoline derivatives for treating cancer |
| 05/26/2004 | EP1420808A1 Treatment of tuberculosis using immunomodulator compounds |
| 05/26/2004 | EP1420805A1 Aromatase marking |
| 05/26/2004 | EP1420804A1 Methods and compositions for control of coccidiosis |
| 05/26/2004 | EP1420803A1 Method for amplifying expression from a cell specific promoter |
| 05/26/2004 | EP1420802A1 Increased solubility flavanolignan preparations |
| 05/26/2004 | EP1420801A1 Use of fucans in the treatment of adhesions, arthritis and psoriasis |
| 05/26/2004 | EP1420800A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity |
| 05/26/2004 | EP1420799A2 Use of atazanavir in hiv therapy |
| 05/26/2004 | EP1420798A2 Treatment and prevention of heat shock protein-associated diseases and conditions |
| 05/26/2004 | EP1420797A1 Dermal therapy using phosphate derivatives of electron transfer agents |
| 05/26/2004 | EP1420796A1 Androgen receptor modulators and methods of use thereof |
| 05/26/2004 | EP1420795A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| 05/26/2004 | EP1420794A1 Prostaglandin analogs as chloride channel opener |
| 05/26/2004 | EP1420793A1 Method and composition for treatment of ocular hypertension and glaucoma |
| 05/26/2004 | EP1420792A2 Products and drug delivery vehicles |
| 05/26/2004 | EP1420791A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma |
| 05/26/2004 | EP1420790A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 05/26/2004 | EP1420789A1 USE OF ACTIVE INGREDIENTS HAVING A $g(m)-OPIOID RECEPTOR AGONIST ACTION AND AN OPIOID RECEPTOR ANTAGONIST ACTION, AS COMBINATION DRUGS FOR THE TREATMENT OF CANCER |
| 05/26/2004 | EP1420788A1 Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders |
| 05/26/2004 | EP1420787A2 Ophthalmic composition comprising an ascomycin |
| 05/26/2004 | EP1420786A2 Methods of inhibiting formation of vascular channels and proliferation using pyridinone derivatives |
| 05/26/2004 | EP1420785A2 SUBSTITUTED INDENO 1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF |
| 05/26/2004 | EP1420784A1 Compounds effecting glucokinase |
| 05/26/2004 | EP1420783A1 Stable emulsion composition |
| 05/26/2004 | EP1420782A1 Use of nefiracetam for treating neurodegeneration |
| 05/26/2004 | EP1420781A2 Analgetic pyrroline derivatives |
| 05/26/2004 | EP1420780A2 Cyclopropyl and cyclobutyl epothilone analogs |
| 05/26/2004 | EP1420778A2 Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| 05/26/2004 | EP1420777A2 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| 05/26/2004 | EP1420776A1 Drugs for treatment of cerebral injury and methods of use thereof |
| 05/26/2004 | EP1420775A1 Platinum complexes and their use in cancer treatment |
| 05/26/2004 | EP1420774A1 Preparation and diabetic use of gibberellins |
| 05/26/2004 | EP1420773A1 Amidine derivatives for treating amyloidosis |
| 05/26/2004 | EP1420772A2 Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases |
| 05/26/2004 | EP1420771A2 Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives, and benzoyl derivatives in the treatment and/or prophylaxis of obesity and accompanying diseases and/or secondary diseases |
| 05/26/2004 | EP1420770A1 Photoreactive compounds and compositions |
| 05/26/2004 | EP1420769A2 Lipid profile modulation with steroids |
| 05/26/2004 | EP1420768A2 Methods and compositions for regulating memory consolidation |
| 05/26/2004 | EP1420767A1 Compositions containing itraconazole and their preparation methods |
| 05/26/2004 | EP1420766A1 Bilayered dispersible tablet formulation comprising amoxycillin and clavulanate in separate layers |
| 05/26/2004 | EP1420762A1 Residual solvant extraction method and microparticles produced thereby |
| 05/26/2004 | EP1420760A2 Aerosolized decongestants for the treatment of sinusitis |
| 05/26/2004 | EP1420759A2 Pharmaceutical compositions for the treatment of asthma |
| 05/26/2004 | EP1420757A2 Cosmetic preparation |
| 05/26/2004 | EP1420750A2 Method of reducing hair growth by applying alpha-difluoromethylornithine |
| 05/26/2004 | EP1420747A2 Benzoquinone ansamycins |
| 05/26/2004 | EP1420745A2 Use of r-nsaid compounds for anti-hiv treatment |
| 05/26/2004 | EP1420743A2 Cholesterol sulfate and amino sugar compositions for enhancement of stratum corneum function |
| 05/26/2004 | EP1420716A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues |
| 05/26/2004 | EP1420646A1 Antimicrobial agent |
| 05/26/2004 | EP1420645A1 Multivesicular emulsion topical delivery systems |
| 05/26/2004 | EP1420644A1 Substituted propargylamines |
| 05/26/2004 | EP1420643A2 Enhancement of transfection of dna into the liver |
| 05/26/2004 | EP1339703B1 A process for the preparation of paclitaxel |
| 05/26/2004 | EP1328269B1 Association of a cb1 receptor antagonist and sibutramin for treating obesity |
| 05/26/2004 | EP1322315A4 Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid |
| 05/26/2004 | EP1305082B1 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 05/26/2004 | EP1303478B1 Process for the preparation of substituted octanoyl amides |
| 05/26/2004 | EP1299095B1 Clear aqueous anaesthetic composition |
| 05/26/2004 | EP1296996B1 Purine derivatives |
| 05/26/2004 | EP1265612B1 Pharmaceutical composition comprising pemetrexed together with monothioglycerol, l-cystein or thioglycolic acid |
| 05/26/2004 | EP1257553B1 Pyrrolopyrimidinone derivatives, process of preparation and use |
| 05/26/2004 | EP1218402B1 Novel betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis |
| 05/26/2004 | EP1216245B1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 05/26/2004 | EP1206474B1 Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| 05/26/2004 | EP1206446B1 Carboxylic acid amides, their production and their use as drugs |
| 05/26/2004 | EP1206258B1 Compositions containing esters for treating parasitic infestations of organisms |
| 05/26/2004 | EP1187605A4 Non-malignant disease treatment with ras antagonists |
| 05/26/2004 | EP1173176B1 Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity |
| 05/26/2004 | EP1165074B1 Viral treatment |
| 05/26/2004 | EP1161226B1 Phosphocholine linked prodrug derivatives |
| 05/26/2004 | EP1137645B1 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group |